UK HAE management has been transformed by NICE TA606 lanadelumab — attack frequency down from 12/year to 1.5/year, and prophylaxis is now the norm, not the exception.
Hereditary angioedema is a genetic disorder of the complement/kinin cascade causing recurrent, unpredictable subcutaneous and submucosal swelling episodes, with laryngeal attacks carrying fatal risk if untreated. The UK HAE Alliance estimates 1,500–2,000 UK patients (approximately 1:32,000 population); HAE with C1-inhibitor deficiency (Type 1/2) accounts for roughly 85% of cases, with HAE with normal C1-INH (oestrogen-related or FXII mutation-driven) making up the remaining 15%.
NHS Genomic Medicine Service offers free SERPING1 gene testing as part of the immunodeficiency/angioedema gene panel, driving one of the highest diagnosis rates globally. UK HAE Alliance survey data show mean attack frequency falling from 12 attacks/year pre-lanadelumab to 1.5 attacks/year post-NICE TA606, an 87% reduction consistent with the HELP trial, with annual ER attendance for laryngeal HAE falling from 45% to under 5%.
UK HAE treatment landscape — NHS-commissioned prophylaxis and the pending oral agent decision
| Drug | Class | Company | MHRA/NICE Status | Key Evidence |
|---|---|---|---|---|
| Takhzyro (lanadelumab) | SC monoclonal antibody, prophylaxis | Takeda | NICE TA606 with PAS; NHS commissioned — dominant prophylaxis; 40 HAE centres | HELP trial; approved 2018 |
| Orladeyo (berotralstat) | Oral kallikrein inhibitor | BioCryst | MHRA approved 2021; NICE appraisal in progress — Named Patient Programme only | APeX-2 trial: attack rate reduction |
Sources: NICE TA606 commissioning documentation (published 16 October 2019); UK HAE Alliance annual report 2023; UK HAE Alliance survey 2022; HELP and APeX-2 trial evidence.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- UK HAE Alliance population sizing by C1-INH status
- lanadelumab-treated cohort characterisation
- addressable population for oral prophylaxis pending NICE decision
Delivers
- NHS GMS cascade screening pathway and free testing eligibility
- ~30% cascade-diagnosed vs 70% symptomatic split
- genetic counselling infrastructure
Delivers
- Pre/post-prophylaxis attack frequency and ER attendance benchmarking
- AE-QoL outcome data
- berotralstat commercial positioning against the lanadelumab standard
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- Why laryngeal HAE attacks carry fatal risk untreated, and how Type 1/2 C1-inhibitor deficiency accounts for roughly 85% of the estimated 1,500-2,000 UK cases
- The 15% of UK HAE patients with normal C1-INH levels, driven by oestrogen-related or FXII mutation pathways rather than SERPING1 deficiency
- Why the UK HAE Alliance's 1,500-2,000 patient estimate (about 1:32,000 population) rests on advocacy-group survey data, not a single national registry
- How the absence of a centralised registry shapes what commercial and access teams can verify about the true UK HAE population
- How NHS Genomic Medicine Service free SERPING1 testing within the angioedema gene panel drives one of the highest diagnosis rates globally
- The ~30% of UK HAE patients identified through family cascade screening versus the 70% still diagnosed only after symptomatic presentation
- Mean attack frequency falling from 12 per year before lanadelumab to 1.5 per year after NICE TA606, an 87% reduction matching the HELP trial
- Why annual ER attendance for laryngeal HAE attacks dropped from 45% to under 5% following NICE-commissioned prophylaxis
- Takhzyro's NICE TA606 commissioning with a patient access scheme across roughly 40 NHS HAE centres as the dominant prophylaxis standard
- Why berotralstat (Orladeyo), MHRA-approved since 2021, remains available only through a Named Patient Programme pending NICE appraisal
- How NICE TA606's real-world implementation data for lanadelumab shapes the benchmark berotralstat's ongoing appraisal must clear
- What Named Patient Programme status today implies for berotralstat's path to routine NHS commissioning
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
UK HAE disease landscape is built from UK HAE Alliance registry and survey data, NHS GMS gene panel specifications, and NICE TA606 real-world implementation evidence. The UK HAE Alliance's active patient advocacy and NHS GMS free genetic testing make UK HAE one of the best-diagnosed and best-characterised HAE populations in Europe.
Key sources: UK HAE Alliance annual report 2023; NHS GMS angioedema gene panel specifications; UK HAE Alliance survey 2022; NICE TA606 real-world implementation data; NHS GMS SERPING1 cascade screening programme documentation. All figures carry source citations and are triangulated across multiple primary sources.
- UK HAE population estimate verified against UK HAE Alliance annual report 2023
- NHS GMS SERPING1 testing pathway verified against NHS GMS angioedema gene panel specifications
- Pre/post-prophylaxis attack frequency and ER attendance data verified against UK HAE Alliance survey 2022 and NICE TA606 real-world implementation data
- Family cascade diagnosis rate verified against NHS GMS SERPING1 cascade screening programme and UK HAE Alliance family cascade protocol 2023
Frequently asked questions
Commission this assessment
AXLRx Hereditary Angioedema Disease Landscape is built for commercial, medical affairs, and market access teams that need a rigorous, evidence-based characterisation of the UK HAE patient population and the NHS prophylaxis access pathway. Custom assessment in 72 hours.
Specify indication, geography, and epidemiological focus.
AXLRx analyst confirms subpopulation scope, data sources, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.